<DOC>
	<DOCNO>NCT02465645</DOCNO>
	<brief_summary>After successful screen patient base inclusion criterion , measure baseline Hepatic Venous Pressure Gradient . At day 1 patient undergo complete blood investigation include complete haemogram , kidney function test , liver function test , prothrombin time , AFP ( Alfa Feto Protein ) level , chest x ray , ultrasonography , fibroscan . Routine complete physical examination do .</brief_summary>
	<brief_title>To Compare Efficacy Safety Carvedilol With Without Simvastatin Patients With Portal Hypertension Esophageal Varices .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . All patient chronic liver disease esophageal varix . 2 . Age equal 18 year . 1 . Patients chronic liver disease history upper Gastro Intestinal bleed . 2 . Patients acute chronic liver failure 3 . Thrombosis splenoportal axis 4 . Hepatocellular carcinoma 5 . Patients primary variceal ligation session prophylaxis 6 . Patients beta blocker intolerant ( Prior h/o hypotension , bradycardia ) . 7 . Patients contraindicate beta blocker { H/O COPD ( Coronary Obstructive Pulmonary Disease ) , heart block , refractory Ascites , SBP ( Spontaneous Bacterial Peritonitis ) , HRS ( Hepato Renal Syndrome ) } . 8 . Failure give consent inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>